Bhushan Akshikar is a seasoned business leader with a successful track record of over 26 years across several geographies within the pharmaceutical industry. Managing Director @GSK India (For any concerns, please reach out via direct message)

It looks like biotech IPOs are about to become this fall’s breakout comeback. Evommune has just added another data point suggesting that drug developers are warming back up to the idea of going public. #IPO #Evommune #Drug #Biotech #Data #ImmuneDrug #lifesciences

Bristol Myers Squibb Deepens Commitment to In Vivo Cell Therapy Bristol Myers Squibb (BMS) has agreed to acquire Orbital Therapeutics for $1.5 billion in cash, deepening its involvement in in vivo cell therapy. #Bristol #vivo #BMS #vivocell #RNA #Orbital #Cash #LifeSciences

New Hope for High-Risk Skin Cancer Patients FDA has approved Regeneron Pharmaceuticals’ Libtayo (cemiplimab) as the first immunotherapy for adjuvant treatment of cutaneous squamous cell carcinoma (CSCC). #FDA #FDAApproved #Regeneron #Cancer #CSCC #Libtayo #LifeSciences

Shivam Puri brings the edge and discipline of 16 years of sales and marketing experience in the diverse Indian FMCG sector to the world of healthcare. #leadership #recognized #lifesciences

Chugai Pharmaceutical has entered into a research collaboration with Singapore-based Gero to develop antibody-based therapies targeting age-related diseases. #Chugai #Gero #partner #Develop #antibodies #disease #AI #lifesciences

Welcome to this week’s edition of the Life Sciences Voice Top Five Newsletter, your go-to source for the latest breakthroughs in the life sciences industry! https://t.co/Yt5Ut4vgui #top5 #newsletter #moderna #Argenex #BerGenBio #Oncoinvent #LifeSciences

FDA has granted accelerated approval to Regeneron’s bispecific antibody linvoseltamab, now branded as Lynozyfic, for the treatment of relapsed or refractory multiple myeloma in patients who have received at least four prior lines of therapy. #FDA #Regeneron #lifesciences

4D Molecular Therapeutics (4DMT) is pressing ahead with its late-stage gene therapy ambitions even as it undergoes significant internal restructuring. #4dmt #Phase3 #EyeGene #therapy #trials #lifesciences

CHMP of the European Medicines Agency issued a positive recommendation for the conditional authorisation of Rezdiffra (resmetirom), developed by Madrigal Pharmaceuticals. #EMA #Mash #treatment #EU #lifesciences

GSK has licensed its Shigella vaccine candidate, altSonflex1-2-3, to Bharat Biotech International Limited (BBIL), an Indian biotechnology firm. #GSK #Shigella #vaccine #BharatBiotech #indian #biotechnology #lifesciences

UroGen Pharma has received FDA approval for its intravesical therapy, Zusduri, marking the first authorized treatment specifically for adult patients in the U.S. diagnosed with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). #FDA #Approves

NextCure has signed a licensing deal valued at up to $745 million for the rights outside Greater China to Simcere Zaiming’s experimental cancer therapy, SIM0505. #NextCure #signs #simcere #zaiming #deal #china #ADC #Cancer #therapy #LifeSciences

As President of the US unit for Novartis, Victor Bultó is pursuing a bold strategy to reimagine medicine and deliver on the company’s responsibility to unlock the potential for helping patients in the world’s largest healthcare market. #leadership #Novartis #LifeSciences

Insmed has announced favorable outcomes from its phase 2b clinical trial assessing treprostinil palmitil inhalation powder (TPIP) in patients with pulmonary arterial hypertension (PAH). #Insmed #Reports #Phase2 #Inhaled #PAH #treatment #Tpip #lifesciences

The U.S. Food and Drug Administration has approved Merck’s monoclonal antibody, clesrovimab, which will be marketed as Enflonsia. #FDA #Merck #enflonsia #RSV #prevention #infants #UnitedStates #lifesciences

Seyltx, a clinical-stage biotherapeutics company based in Cambridge, Massachusetts, has announced an option agreement to license a portfolio of eight GluN2B antagonists from Atlanta-based NeurOp. #seyltx #clinicalstage #antagonist #biotherapeutic #Phase1 #lifesciences

Nominations now open for Life Sciences Voice Rising Stars Award 2025! Recognizing Emerging Leaders Shaping the Future of Life Sciences Nominate Now: https://t.co/1YOipJkp8k #RisingStars #Awards2025 #awards #risingstarsaward #nominations #UnitedStates #lifescivoice #lifesciences

Nominations now open for Life Sciences Voice Rising Stars Award 2025! Recognizing Emerging Leaders Shaping the Future of Life Sciences Nominate Now: https://t.co/1nA2TRZLNb #RisingStars #Awards2025 #awards #risingstarsaward #nominations #LifeSciences #UnitedStates #lifescivoice

https://t.co/VgYCq6IEoG